ReviewThe Korean journal of internal medicine2019
The epidemiology of hepatitis B virus infection in Korea.
Review in The Korean journal of internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer.ESMO open · 2024Guideline
- A Korean Clinical Practice Framework for Thyroid Eye Disease: Integrating International Recommendations with Survey-Informed Consensus.Endocrinology and metabolism (Seoul, Korea) · 2026Article
- Persistent hepatitis burden in a geographically isolated and medically underserved population: a community-based study.Scientific reports · 2026Article
- Malignant Hepatocellular Neoplasm, Not Otherwise Specified, Displays Poorer Chemoresponsiveness and Postoperative Prognosis Than Hepatoblastoma.Cancer research and treatment · 2026Article
- Global, regional, and national burden and trends of liver cancer due to hepatitis B in young adults from 1990 to 2021 and forecast to 2030: insights from the Global Burden of Disease Study 2021.Internal and emergency medicine · 2026Article
- Analysis of Clinical Characteristics and Treatment Efficacy in the Korean Hepatitis B Cohort.Public health weekly report · 2026Article
- Burden of hepatitis B virus-associated liver cancer in Asia: findings from the global burden of disease study.Frontiers in public health · 2026Article
- Long-Term Cancer Incidence Trends in Korea (2001-2020): An Age-Period-Cohort and Joinpoint Analysis with a Focus on Younger Cohorts.Medicina (Kaunas, Lithuania) · 2025Article
- Changes in antiviral treatment rate for hepatitis B virus before hepatocellular carcinoma diagnosis: a nationwide Korean study.European journal of gastroenterology & hepatology · 2025Article
- Decreasing hepatitis B seroprevalence in pregnant women in Taiwan between 2016 and 2021: a claim-based cohort study.BMC public health · 2025Article
- Phylodynamics of hepatitis B virus genotype B in East Asia: A population genomics analysis.Journal of biological methods · 2025Article
- Geographic diversity of human liver cancers mirrors global social inequalities.Frontiers in oncology · 2025Review
- Global burden of liver cirrhosis 1990-2019 and 20 years forecast: results from the global burden of disease study 2019.Annals of medicine · 2024Article
- Impact of Korean Military Service on the Prevalence of Steatotic Liver Disease: A Longitudinal Study of Pre-enlistment and In-Service Health Check-Ups.Gut and liver · 2024Article
- Evaluation of the acute hepatitis B surveillance system in the Republic of Korea following the transition to mandatory surveillance.Osong public health and research perspectives · 2024Article
- The Epidemiology of Hepatitis B Virus Infection in Korea: 15-Year Analysis.Journal of Korean medical science · 2024Article
- Assessment of Disease Burden and Immunization Rates for Vaccine-Preventable Diseases in People Living with HIV: The Korea HIV/AIDS Cohort Study.Infection & chemotherapy · 2023Article
- Impact of hepatitis B virus infection on the risk of gallbladder polyps: a cohort study.The Korean journal of internal medicine · 2023Article
- Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea.Infectious diseases and therapy · 2023Article
- Etiology and clinical characteristics of acute viral hepatitis in South Korea during 2020-2021: a prospective multicenter study.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global burden of hepatitis B virus (HBV) infection is profound, and represents a public health threat as chronic infection can lead to liver cirrhosis, hepatocellular carcinoma, and death. The risk factors for chronic hepatitis B-related liver disease differ according to HBV endemicity, hepatitis B e-antigen seropositivity, and viral load. It is important to identify these risk factors and start antiviral treatment at an appropriate time according to current guidelines. The most crucial step in reducing HBV infection is prevention in infancy or early childhood, as infection at an early stage may lead to chronicity. South Korea was formerly an HBV-endemic area, but the epidemiology of HBV infection was changed by the introduction of vaccination in 1983 and nationwide immunization in 1995. The government and the private sector made efforts to reduce the prevalence of HBV infection, and Korea is on target to meet the World Health Organization goal of eliminating viral hepatitis by 2030. To eliminate hepatitis worldwide, the costs of antiviral treatment to prevent perinatal HBV transmission in pregnant women with high viremia should be covered by a national program, and strategies to reduce the prevalence of HBV infection in immigrant populations are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.